Quick Win By The Algorithm: Omeros Receives Encouraging Clinical Trial Data

Omeros Corporation (OMER)

Omeros Corporation (OMER) was a top stock pick based on predictive algorithm. OMER had a signal of 14.76 and a predictability of 0.11. In accordance with the algorithm, the company reported short-term capital gains of 12.37%

Quick WIn

Omeros Corporation (OMER), is a biopharmaceutical company which develops a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery, and pain management.  Omeros is in development of numerous drugs.  In April 2015, Omeros released OMIDRIA®, a drug used during cataract surgery or intraocular lens replacement.  Founded in 1994, the company is headquartered in Seattle,Washington.


In the BioTech sector, a drug’s development or clinical trial results could influence the stock’s performance, especially for small-cap stocks.  Such positive trial could influence the FDA to approve the drug to be marketed and distributed.  This is the case with Omeros.  On November 3rd, Omeros filed an application for a drug to treat immunoglobulin A (IgA) nephropathy or Berger’s disease.  If the drug receives approval, it could be used to treat up to 200,000 Americans affected by this.  Besides filing the application, Omeros received encouraging clinical reports from their development in other drugs.  The company recieved positive data in Phase 2 for both atypical hemolytic uremic syndrome and hematopoietic stem cell-associated TMA.

These encouraging news not only increased the stock price, but also influenced Maxim Group to give favorable ratings.  The next day, Maxim Group gave a buy rating and a price target of $19.00.  That is more than a potential upside of over 100% from November 4, 2016 closing price.

This bullish forecast on OMER was sent to current I Know First subscribers on Novebmer 3rd, 2016. 

Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Missed the latest trend? Looking for the next best market opportunity? Find out today’s stock forecast based on our advanced self-learning algorithm